Pregnant women with COVID-19 face high mortality rate
In a worldwide study of 2,100 pregnant women, those who contracted COVID-19 during pregnancy were 20 times more likely to die than those who did not contract the… read more.
In a worldwide study of 2,100 pregnant women, those who contracted COVID-19 during pregnancy were 20 times more likely to die than those who did not contract the… read more.
Infection with parasitic intestinal worms (helminths) can apparently cause sexually transmitted viral infections to be much more severe elsewhere in the body.
Infants born by cesarean section have a relatively meager array of bacteria in the gut. But by the age of three to five years they are broadly in… read more.
Lupin Pharma, a subsidiary of global pharma major Lupin Ltd, announced a partnership with Endoceutics, a women’s health focused innovative Canadian biotech company, to commercialize Intrarosa in Canada.
Interview and article by Christine Clark Dr Peter English, a consultant in communicable disease control describes the UK HPV vaccination strategy and the associated issues. Dr Peter English,… read more.
Interview and article by Christine Clark Cervical cancer accounts for about 850 cancer deaths in the UK every year – more than two every day – and yet… read more.
ViiV Healthcare, owned by GlaxoSmithKline, announced the European Marketing Authorisation of Rukobia (fostemsavir) 600mg extended-release tablets..
Low levels of key, body-regulating chemicals in mothers during the first three months of pregnancy may interfere with the baby’s brain development, a large American study shows.
The human gut contains a diverse ecosystem of microbes: mainly bacteria, as well as viruses and fungi, termed the gut microbiota. Recent years have shown that the gut… read more.
Evofem Biosciences, Inc. announced that the FDA has approved Phexxi (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive… read more.
Myovant Sciences announced that the journal Obstetrics & Gynecology has published three abstracts detailing additional efficacy and safety findings from the Phase III LIBERTY 1 and 2 studies… read more.
Myovant Sciences announced that the journal Obstetrics & Gynecology has published three abstracts detailing additional efficacy and safety findings from the Phase III LIBERTY 1 and 2 studies… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.